Review highlights the development of small-molecule inhibitors targeting peptidoglycan hydrolases, indicating potential for antimicrobial therapies.
The growing number of bacterial infections and the rise of antibiotic resistance require approaches for antimicrobial development. Peptidoglycan, essential for maintaining the integrity and shape of the bacterial cell wall, is regulated by the coordinated activity of peptidoglycan synthesis and remodeling enzymes. While peptidoglycan synthesis enzymes have served as antibiotic targets for decades, peptidoglycan hydrolases have remained largely underexplored. Here, we review recent advances in the development of small-molecule inhibitors of peptidoglycan hydrolases as antimicrobial targets.
No takes yet. Share an insight, caveat, or question.
Fam et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: